Patterns of drug utilization in a neonatal intensive care unit

Journal of Clinical Pharmacology

Volumn 46, Issue 4, 2006, Pages 449-455

  Warrier, Indulekha ^a,b   Du, Wei ^a   Natarajan, Girija ^a   Salari, Vali ^a   Aranda, Jacob ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Drug utilization; Neonatal intensive care unit; Neonate

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BERACTANT; CAFFEINE; CALCIUM; CEFOTAXIME; CHLOROTHIAZIDE; DEXAMETHASONE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FLUCONAZOLE; FLUCYTOSINE; FUROSEMIDE; HYPERTENSIVE AGENT; INDOMETACIN; IRON; NYSTATIN; PENICILLIN G; RESPIRATORY TRACT AGENT; SPIRONOLACTONE; SURFACTANT; THEOPHYLLINE; VANCOMYCIN;

AFRICAN AMERICAN; ARTICLE; BIRTH WEIGHT; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DEMOGRAPHY; DRUG UTILIZATION; FEMALE; FREQUENCY ANALYSIS; GENDER; GESTATIONAL AGE; HIGH RISK INFANT; HISPANIC; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; NEWBORN; NEWBORN CARE; NEWBORN INTENSIVE CARE; PERINATAL DRUG EXPOSURE; POPULATION RESEARCH; PREDICTION; PREMATURITY; RACE; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL DISTRIBUTION; SURVIVAL; TERTIARY HEALTH CARE;

AFRICAN AMERICANS; BIRTH WEIGHT; DRUG UTILIZATION REVIEW; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GESTATIONAL AGE; HISPANIC AMERICANS; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; LENGTH OF STAY; MALE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE;

EID: 33644972344     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005285456     Document Type: Article

References (35)

1. Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA. 2003;290:905-911.
2. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 2002;300:355-360.
3. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Thee. 2002;300:361-366.
4. Ten Eick AP, Reed MD. Clinical pharmacology research in the pediatric patient: the challenge continues. Prog Pediatr Cardiol. 2000;12:29-35.
5. Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin Drug Saf. 2004;3:81-83.
6. Assael BM. Therapeutic orphans: European perspective. Pediatrics. 1999;104(Pt 2):591-592.
7. Survey of the current state of pediatric drug use in Japan (1994-6). Drug Therapy Committee of the Japan Pediatric Society. Pediatr Int. 2000;42:109-113.
8. Bonati M. Epidemiologic evaluation of drug use in children. J Clin Pharmacol. 1994;34:300-305.
9. Gortner L. Drug utilisation in preterm and term neonates. Pharmacoeconomics. 1993;4:437-445.
10. Lesko SM, Epstein MF, Mitchell AA. Recent patterns of drug use in newborn intensive care. J Pediatr. 1990;116:985-990.
11. Aranda JV, Cohen S, Neims AH. Drug utilization in a newborn intensive care unit. J Pediatr. 1976;89:315-317.
12. Early neonatal drug utilization in preterm newborns in neonatal intensive care units. Italian Collaborative Group on Preterm Delivery. Dev Pharmacol Ther. 1988;11:1-7.
13. Blumer JL, Reed MD. Principles of neonatal pharmacology. In: Yaffe SJ, Aranda JV, eds. Neonatal and Pediatric Pharmacology. 3rd ed. Baltimore: Lippincott, Williams & Wilkins; 2005:146-158.
14. van den Anker JN. Managing drugs safely. Semin Fetal Neonatal Med. 2005;10:73-81.
15. Knight M. Adverse drug reactions in neonates. J Clin Pharmacol. 1994;34:128-135.
16. Aranda JV. Factors associated with adverse drug reactions in the newborn. Pediatr Pharmacol 1983;3:245-249.
17. Aranda JV, Clarkson S, Collinge JM. Changing pattern of drug utilization in a neonatal intensive care unit. Am J Perinatol. 1983;1:28-30.
18. Daniell AJ, Darlow BA. Audit of drug usage in a regional neonatal intensive care unit. Aust Paediatr J. 1989;25:207-210.
19. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17:638-680.
20. Roilides E, Farmaki E, Evdoridou J, et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis. 2004;23:745-750.
21. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998;17:504-508.
22. Stratov I, Gottlieb T, Bradbury R, O'Kane GM. Candidaemia in an Australian teaching hospital: relationship to central line and TPN use. J Infect. 1998;36:203-207.
23. Johnsson H, Ewald U. The rate of candidaemia in preterm infants born at a gestational age of 23-28 weeks is inversely correlated to gestational age. Acta Paediatr. 2004;93:954-958.
24. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol. 2003;188:1039-1045.
25. Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: the MAP study. Aust N Z J Obstet Gynaecol. 2000;40:165-172.
26. Alexander GR, Kogan M, Bader D, Carlo W, Allen M, Mor J. US birth weight/gestational age-specific neonatal mortality: 1995-1997 rates for whites, Hispanics, and blacks. Pediatrics. 2003;111:e61-6.
27. Stevenson DK, Verter J, Fanaroff AA, et al. Sex differences in outcomes of very low birthweight infants: the newborn male disadvantage. Arch Dis Child Fetal Neonatal Ed. 2000;83:F182-F185.
28. Spitzer AR, Kirkby S, Kornhauser M. Practice variation in suspected neonatal sepsis: a costly problem in neonatal intensive care. J Perinatol. 2005;25:265-269.
29. Toledano H, Schlesinger Y, Raveh D, et al. Prospective surveillance of vancomycin-resistant enterococci in a neonatal intensive care unit. Eur J Clin Microbiol Infect Dis. 2000;19:282-287.
30. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000;106:1387-1390.
31. Dasgupta SJ, Gill AB. Hypotension in the very low birthweight infant: the old, the new, and the uncertain. Arch Dis Child Fetal Neonatal Ed. 2003;88:F450-F454.
32. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2002;1:CD001817.
33. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-2120.
34. Gonzalez-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients: a prospective study. Int J Clin Pharmacol Ther. 1998;36:530-533.
35. Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer JM, Rubio E, Morales Olivas FJ. A prospective study of adverse drug reactions in hospitalized children. Br J Clin Pharmacol. 1999;47:681-688.